853
Views
23
CrossRef citations to date
0
Altmetric
Research Article

Performance of the Framingham and SCORE cardiovascular risk prediction functions in a non-diabetic population of a Spanish health care centre: a validation study

, , , , &
Pages 242-248 | Received 15 May 2009, Accepted 18 Aug 2010, Published online: 27 Sep 2010

References

  • Sans S, Kestekoot H, Kromhout D. The burden of cardiovascular disease mortality in Europe. Task Force on the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231–48.
  • Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P . Contributions of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999;353:1545–57.
  • Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörala K. Task Force Report. Prevention of coronary heart disease in clinical practice: Recommendations of the second joint task force of the joint European Societies on coronary prevention. Eur Heart J 1998;19:1434–1503.
  • Expert Panel. On detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
  • Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;109: 3112–21.
  • Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: A statement for health professionals. Circulation 1991;83:356–62.
  • Wilson PWF, D’Agostino RB, Levy D, . Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47.
  • Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in Northern and Southern Europeans populations: A reanalysis of the seven countries study for a European coronary risk chart. Heart 2000;84:238–44.
  • Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart risk function from an Italian population study. Eur Heart J 2000;21: 365–70.
  • Marrugat J, D’Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J . An adaptation of the Framingham coronary risk function to southern Europe Mediterranean areas. J Epidemiol Community Health 2003;57:634–8.
  • Cañón Barroso L, Cruces E, Fernández G, Nieto T, García-Vellido A, Buitrago F. Validación de tres ecuaciones de riesgo coronario en población diabética de un centro de salud (Validation of three equations of coronary risk in diabetic population of a primary care centre. English summary) Med Clin (Barc) 2006;126:485–90.
  • Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany: Results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;24:937–45.
  • Thomsen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002;31: 817–22.
  • Empana JP, Ducimetiere P, Arvelier D, Ferrieres J, Evans A, Ruidavets JB, . Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2004;24:1903–11.
  • Marrugat J, Solanas P, D’Agostino R, Sullivan L, Ordovas J, Cordón F, . Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada (Coronary risk estimation in Spain using a calibrated Framingham function. English summary). Rev Esp Cardiol 2003;56:253–61.
  • Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, . Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987–1003.
  • De Backer G, Ambrosioni E, Broch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, . Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601–10.
  • Brotons C, Royo-Bordonada MA, Alvárez-Sala L, Armario P, Artigao R, Conthe P, . Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC). Adaptación española de la Guía Europea de Prevención Cardiovascular (Spanish adaptation of the European Guidelines on Cardiovascular Disease Prevention. English summary). Rev Esp Salud Pública 2004;78:435–8.
  • Kee F, Owen T, Leathem R. Offering a prognosis in lung cancer: When is a team of experts an expert team? J Epidemiol Community Health; 2007;61:308–13.
  • Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PMM. The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol 2003;56:1129–35.
  • De Backer G, Ambrosioni E, Broch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, . Resumen ejecutivo. Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Tercer grupo de trabajo de las Sociedades Europeas y otras Sociedades sobre Prevención Cardiovascular en la Práctica clínica. Rev Esp Salud Pública 2004;78:439–56.
  • Färnkvist L, Olofsson N, Weinehall L. Did a health dialogue matter? Self-reported cardiovascular disease and diabetes 11 years after health screening. Scand J Prim Health Care 2008;26:135–9.
  • Björkelund C, Andersson-Hange D, Andersson K, Bengtsson C, Blomstrand A, Bondyr-Carlsson D, . Secular trends in cardiovascular risk factors with a 36-year perspective: Observations from 38- and 50-year-olds in the Population Study of Women in Gothenburg. Scand J Prim Health Care 2008;26:140–6.
  • Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España (Calibrating the SCORE cardiovascular risk chart for use in Spain. English summary). Rev Esp Cardiol 2007;60:476–85.
  • Marrugat J, Subirana I, Comín E, Cabezas C, Vils J, Elosua R, , for the VERIFICA (Validez de la Ecuación de Riesgo Individual de Framingham de Incidentes Coronarios Adaptada) investigators. Validity of an adaptation of the Framingham cardiovascular risk function: The VERIFICA study. J Epidemiol Community Health 2007;61:40–7.
  • Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: A validation study. Heart 2008;94:34–9.
  • Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: A prospective open cohort study. BMJ 2009;339;b2584. doi:10.1136/bmj.b2584.
  • Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: A prospective open cohort study. BMJ 2010;340;c2442. doi: 10.1136/bmj.c2442.
  • Goodyear-Smith F, Arroll B, Chan L, Jackson R, Wells S, Kenealy T. Patients prefer pictures to numbers to express cardiovascular benefit from treatment. Ann Fam Med 2008;6:213–7.
  • Getz L, Kirkengen AL, Hetlevik I. Too much doing and too little thinking in medical science! Scand J Prim Health Care 2008;26:65–6.